Remove 2011 Remove Healthcare Remove Networking Remove Safety
article thumbnail

Hip Innovation Technology Announces Initiation of FDA Approved Investigational Device Exemption Study

Legacy MEDSearch

The IDE Study is being conducted to determine the safety and effectiveness of the HIT Reverse HRS in Primary Total Hip Arthroplasty (THA). Safety will be assessed through the collection of device-related adverse events and patient quality of life metrics. About Hip Innovation Technology, LLC.

FDA 98
article thumbnail

The Caregiver Vertical: How Pharma Engages

Pharma Marketing Network

With an estimated 65 million people serving as caregivers, 1 the role is now a factor in an ever-increasing list of healthcare priorities. If caregiving is positioned as an essential service and caregivers are counted among healthcare’s front-line service providers, 4 does it follow caregivers are a viable healthcare vertical?

Pharma 98
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Three Steps to Hitting Your MLR Targets in 2021 

Clarify Health

Prior to 2011 when the Affordable Care Act (ACA) was passed, many insurance companies were spending a large portion of premium dollars on administrative costs and profits. Health plans should prioritize high-value providers to include in their network based on case-mix adjusted clinical, quality and cost-efficiency scores.

article thumbnail

Paving the way for anti-Abeta active immunotherapy

European Pharmaceutical Review

Active immunotherapy through vaccination has a far lower cost than mAb-based therapies, representing an important decrease of economic burden for healthcare systems at a global scale. 7 It is currently being evaluated in a Phase Ib/IIa clinical study, demonstrating to date a good safety profile.

article thumbnail

Using RWE in rare disease drug development: effective innovations with historical controls

European Pharmaceutical Review

Additionally, healthcare payers understand that HCs can provide value by describing potential treatment benefit relative to untreated patients in their populations. Healthcare payers also use clinical trial evidence to assess the effectiveness of treatments in making reimbursement decisions. 2011 May; 46(3): 399–424.

article thumbnail

Yotam Drechsler & Yaron Segal

Cadensee

Because we see these frequencies as kind of signatures, access codes to different networks that have been impaired in the brain as their own, as described before, and facilitating their recovery. I would love to hear a little bit more about the issue of neural networks and the technology. How does your technology work?